Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Gene therapy of cystic fibrosis (CF) airways: A review emphasizing targeting with lactose

Identifieur interne : 002382 ( Main/Exploration ); précédent : 002381; suivant : 002383

Gene therapy of cystic fibrosis (CF) airways: A review emphasizing targeting with lactose

Auteurs : Daniel T. Klink [États-Unis] ; Mary Catherine Glick [États-Unis] ; Thomas F. Scanlin [États-Unis]

Source :

RBID : ISTEX:1EC2341B0A852CAE3EA52ED120E351D7EBC82AA7

English descriptors

Abstract

Abstract: Cystic fibrosis is a disease for which a number of Phase I clinical trials of gene therapy have been initiated. Several factors account for the high level of interest in a gene therapy approach to this disease. CF is the most common lethal inherited disease in Caucasian populations. The lung, the organ that is predominantly responsible for the morbidity and mortality in CF patients, is accessible by a non-invasive method, the inhalation of aerosols. The vectors employed in the Phase I trials have included recombinant adenoviruses, adeno-associated viruses and cationic lipids. While there have been some positive results, the success of the vectors until now has been limited by either immunogenicity or low efficiency. A more fundamental obstacle has been the absence of appropriate receptors on the apical surface of airway epithelial cells. Molecular conjugates with carbohydrate substitution to provide targeting offer several potential advantages. Lactosylated polylysine in which 40% of the lysines have been substituted with lactose has been shown to provide a high efficiency of transfection in primary cultures of CF airway epithelial cells. Other important features include a relatively low immunogenicity and cytotoxicity. Most importantly, the lactosylated polylysine was demonstrated to give nuclear localization in CF airway epithelial cells. Until now, most non-viral vectors did not have the capability to provide nuclear localization. These unique qualities provided by the lactosylation of non-viral vectors, such as polylysine may help to advance the development of molecular conjugates sufficiently to warrant their use in future clinical trials for the gene therapy of inherited diseases of the lung.

Url:
DOI: 10.1023/A:1020879524587


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Gene therapy of cystic fibrosis (CF) airways: A review emphasizing targeting with lactose</title>
<author>
<name sortKey="Klink, Daniel T" sort="Klink, Daniel T" uniqKey="Klink D" first="Daniel T." last="Klink">Daniel T. Klink</name>
</author>
<author>
<name sortKey="Glick, Mary Catherine" sort="Glick, Mary Catherine" uniqKey="Glick M" first="Mary Catherine" last="Glick">Mary Catherine Glick</name>
</author>
<author>
<name sortKey="Scanlin, Thomas F" sort="Scanlin, Thomas F" uniqKey="Scanlin T" first="Thomas F." last="Scanlin">Thomas F. Scanlin</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1EC2341B0A852CAE3EA52ED120E351D7EBC82AA7</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1023/A:1020879524587</idno>
<idno type="url">https://api.istex.fr/ark:/67375/VQC-FTCC2XW6-9/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000868</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000868</idno>
<idno type="wicri:Area/Istex/Curation">000868</idno>
<idno type="wicri:Area/Istex/Checkpoint">001208</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001208</idno>
<idno type="wicri:doubleKey">0282-0080:2001:Klink D:gene:therapy:of</idno>
<idno type="wicri:Area/Main/Merge">002407</idno>
<idno type="wicri:Area/Main/Curation">002382</idno>
<idno type="wicri:Area/Main/Exploration">002382</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Gene therapy of cystic fibrosis (CF) airways: A review emphasizing targeting with lactose</title>
<author>
<name sortKey="Klink, Daniel T" sort="Klink, Daniel T" uniqKey="Klink D" first="Daniel T." last="Klink">Daniel T. Klink</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Cystic Fibrosis Center and Department of Pediatrics, University of Pennsylvania, School of Medicine, The Children's Hospital of Philadelphia, 19104, Philadelphia, PA</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Glick, Mary Catherine" sort="Glick, Mary Catherine" uniqKey="Glick M" first="Mary Catherine" last="Glick">Mary Catherine Glick</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Cystic Fibrosis Center and Department of Pediatrics, University of Pennsylvania, School of Medicine, The Children's Hospital of Philadelphia, 19104, Philadelphia, PA</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Scanlin, Thomas F" sort="Scanlin, Thomas F" uniqKey="Scanlin T" first="Thomas F." last="Scanlin">Thomas F. Scanlin</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Cystic Fibrosis Center and Department of Pediatrics, University of Pennsylvania, School of Medicine, The Children's Hospital of Philadelphia, 19104, Philadelphia, PA</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Glycoconjugate Journal</title>
<title level="j" type="sub">Official Journal of the International Glycoconjugate Organization</title>
<title level="j" type="abbrev">Glycoconj J</title>
<idno type="ISSN">0282-0080</idno>
<idno type="eISSN">1573-4986</idno>
<imprint>
<publisher>Kluwer Academic Publishers-Plenum Publishers</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2001-09-01">2001-09-01</date>
<biblScope unit="volume">18</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="731">731</biblScope>
<biblScope unit="page" to="740">740</biblScope>
</imprint>
<idno type="ISSN">0282-0080</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0282-0080</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>cystic fibrosis</term>
<term>cystic fibrosis airway epithelial cells</term>
<term>gene therapy</term>
<term>gene transfer</term>
<term>lactosylated poly-L-lysine</term>
<term>non-viral vector</term>
<term>nuclear translocation</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Cystic fibrosis is a disease for which a number of Phase I clinical trials of gene therapy have been initiated. Several factors account for the high level of interest in a gene therapy approach to this disease. CF is the most common lethal inherited disease in Caucasian populations. The lung, the organ that is predominantly responsible for the morbidity and mortality in CF patients, is accessible by a non-invasive method, the inhalation of aerosols. The vectors employed in the Phase I trials have included recombinant adenoviruses, adeno-associated viruses and cationic lipids. While there have been some positive results, the success of the vectors until now has been limited by either immunogenicity or low efficiency. A more fundamental obstacle has been the absence of appropriate receptors on the apical surface of airway epithelial cells. Molecular conjugates with carbohydrate substitution to provide targeting offer several potential advantages. Lactosylated polylysine in which 40% of the lysines have been substituted with lactose has been shown to provide a high efficiency of transfection in primary cultures of CF airway epithelial cells. Other important features include a relatively low immunogenicity and cytotoxicity. Most importantly, the lactosylated polylysine was demonstrated to give nuclear localization in CF airway epithelial cells. Until now, most non-viral vectors did not have the capability to provide nuclear localization. These unique qualities provided by the lactosylation of non-viral vectors, such as polylysine may help to advance the development of molecular conjugates sufficiently to warrant their use in future clinical trials for the gene therapy of inherited diseases of the lung.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Pennsylvanie</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Pennsylvanie">
<name sortKey="Klink, Daniel T" sort="Klink, Daniel T" uniqKey="Klink D" first="Daniel T." last="Klink">Daniel T. Klink</name>
</region>
<name sortKey="Glick, Mary Catherine" sort="Glick, Mary Catherine" uniqKey="Glick M" first="Mary Catherine" last="Glick">Mary Catherine Glick</name>
<name sortKey="Scanlin, Thomas F" sort="Scanlin, Thomas F" uniqKey="Scanlin T" first="Thomas F." last="Scanlin">Thomas F. Scanlin</name>
<name sortKey="Scanlin, Thomas F" sort="Scanlin, Thomas F" uniqKey="Scanlin T" first="Thomas F." last="Scanlin">Thomas F. Scanlin</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002382 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002382 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1EC2341B0A852CAE3EA52ED120E351D7EBC82AA7
   |texte=   Gene therapy of cystic fibrosis (CF) airways: A review emphasizing targeting with lactose
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021